Department of Head and Neck Surgery, University Hospital for Tumors, Zagreb, Croatia.
Head Neck. 2010 Sep;32(9):1178-84. doi: 10.1002/hed.21314.
The prognostic value of cancer testis antigens in pharyngeal cancer is understudied.
We recruited 90 patients who were treated for pharyngeal cancer. Monoclonal antibodies 57B and B9.8.1.1 were used for detection of MAGE-A and NY-ESO-1 genes.
MAGE-A and NY-ESO-1 gene products were detectable in 70.0% and 33.3% of pharyngeal tumors, respectively. No correlation was established between MAGE-A and NY-ESO-1 expression and TNM staging at presentation. Survival analysis showed a trend toward a shorter 5-year disease-free survival in the group of patients with MAGE-A-positive tumors (log-rank test, p = .122). In contrast, a trend toward a prolonged 5-year disease-free survival was observed in the group of patients with NY-ESO-1-positive tumors (log-rank test, p = .219).
In a large population of patients with pharyngeal cancer and available 5-year survival data, prognosis tended to be poorer with MAGE-A expression and better with NY-ESO-1 expression, but the correlations did not reach statistical significance.
癌症睾丸抗原在咽癌中的预后价值尚未得到充分研究。
我们招募了 90 名接受咽癌治疗的患者。使用单克隆抗体 57B 和 B9.8.1.1 检测 MAGE-A 和 NY-ESO-1 基因。
在 70.0%的咽肿瘤中可检测到 MAGE-A 基因产物，在 33.3%的肿瘤中可检测到 NY-ESO-1 基因产物。MAGE-A 和 NY-ESO-1 表达与就诊时的 TNM 分期之间未建立相关性。生存分析显示，MAGE-A 阳性肿瘤组患者的 5 年无病生存率较低（对数秩检验，p =.122）。相比之下，NY-ESO-1 阳性肿瘤组患者的 5 年无病生存率有延长趋势（对数秩检验，p =.219）。
在大量具有 5 年生存数据的咽癌患者中，MAGE-A 表达与预后较差相关，NY-ESO-1 表达与预后较好相关，但相关性未达到统计学意义。
